In the validation cohort study using the TCGA database, WHO grade 4 gliomas (n = 153) had significantly higher ACTA2 gene expression than lower-grade gliomas of WHO grades 2 (n = 226) and 3 gliomas (n = 244) (Figure S2, p < 0.001). This evidence concerns the gene ACTA2 and central nervous system cancer.